|
|
|
| home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group |
|
|
 WHITE PAPERS |
|
Synergy Research Group
|
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
|
|
In summary, Russia remains a very popular geography for local, regional,
and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Dotmatics Biology Solution for Antibody Discovery streamlines Data Collection and Workflows to Accelerate Antibody Research and Therapies
Boston, MA, May 3, 2022 – Dotmatics, a leader in R&D
scientific software connecting science, data, and decision-making, today
announced the release of its Biology Solution for Antibody Discovery, a
unique end-to-end software and data management package. The antibody
workflow combines Dotmatics’ enterprise scientific platform with
advanced applications software used routinely in antibody discovery
laboratories including Geneious, SnapGene, and GraphPad Prism. The fully
integrated solution will streamline data collection and processing of
the antibody discovery workflow, facilitating a pathway to more
effective and efficient discovery, and accelerating progress towards
potentially life-changing therapies for patients.
More info >> |
|
 |
White Papers |
 |
|
Characterisation of Biopharmaceutical Proteins
Reading Scientific Services Ltd (RSSL)
Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >> |
|
|
|
